Author of

• 20187

  +

  P3.08 - Locally Advanced Nsclc (ID 724)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Locally Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24123

    +

    P3.08-001 - Concurrent Chemoradio­therapy with Weekly Carboplatin-Paclitaxel May Be Feasible Option in inoperable Stage III NSCLC (ID 9596)

    09:30 - 09:30  |  Author(s): G. Ugurluer
    • Abstract

    Background:
    Concurrent chemoradio­therapy (CCRT) is standard treatment modality for patients with unresectable stage III NSCLC dis­ease. TIn this study, we aimed to investigate the efficacy and toxicity of CCRT with carboplatin (AUC 2) and paclitaxel (80 mg/m2) during radiotherapy.
    
    Method:
    Medical records of 41 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with carboplatin-paclitaxel were retrospectively analyzed. Carboplatin (AUC 2) and Paclitaxel (80 mg/m2) from periph­eral route were administered weekly during radiotherapy
    
    Result:
    41 consecutive unresect­able stage IIIA-B NSCLC patients treated with CCRT were included into this study. Median age was 62 years old (range 40–77), and 37 (90.2%) of the patients were men. ECOG per­formance score was 0 in 23 patients (56.1%). Adenocarcinoma, the most common histology, was diagnosed in 18 pa­tients (43.9%). There were 11 (26,8%) stage IIIA patients and 26 (63.4%) stage IIIB patients. Median follow-up time was 22.5 months. Median PFS and OS were 22.5 and 53.5 months. Hematological and non-hematological grade 3–4 toxicities were seen in 8 (19,5%) and 5 (12.2%) patients, respectively. Figure 1Figure 2
    
    
    
    
    
    Conclusion:
    This study showed that carboplatin-paclitaxel provides results similar to that in the literature survival parameters and it may be an option with lower toxicities for CCRT in patients with unresectable stage III NSCLC.